SCHEMBL2365052

SCHEMBL2365052

CCCCC(N)C(=O)On1cnc2ccccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ASAH1 Q13510 1/20 0.44
APAF1 O14727 1/20 0.40
KDM4E B2RXH2 3/20 0.38
NPC1 O15118 3/20 0.38
LMNA P02545 2/20 0.38
USP2 O75604 1/20 0.38
MGAM O43451 1/20 0.37
AMY1A P0DUB6 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
MAPT P10636 3/20 0.37
ALDH1A1 P00352 2/20 0.37
RAB9A P51151 2/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
EGLN3 Q9H6Z9 1/20 0.36
DNMT3A Q9Y6K1 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11555506 0.80 APAF1 (0.46) APAF1KDM4ENPC1MAPTRAB9A
SCHEMBL3796577 0.76 APAF1 (0.45) ASAH1APAF1KDM4ENPC1LMNA
SCHEMBL9533877 0.76 KDM4E (0.48) KDM4ELMNAGAAMAPTHTT
SCHEMBL27803078 0.74 SMN1; SMN2 (0.45) ASAH1APAF1KDM4ENPC1LMNA
SCHEMBL9378031 0.73 FGFR1 (0.50) ASAH1APAF1KDM4ENPC1MAPT
SCHEMBL1884001 0.72 KMT2A (0.46) APAF1KDM4ENPC1MAPTRAB9A
SCHEMBL158527 0.72 KMT2A (0.46) ASAH1APAF1KDM4ENPC1MAPT
SCHEMBL8901472 0.72 EGLN3 (0.46) ASAH1APAF1KDM4ENPC1HSD17B10
SCHEMBL6392854 0.72 EGLN3 (0.46) ASAH1APAF1KDM4ENPC1MAPT
SCHEMBL10712118 0.71 ASAH1 (0.53) ASAH1KDM4ENPC1LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1831206-B1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY OSI PHARM INC (US) 2011-08-24 EP disclosed
US-7419995-B2 N-substituted benzimidazoyl c-Kit inhibitors and combinatorial benzimidazole library OSI PHARMACEUTICALS, INC. (US) 2008-09-02 US disclosed
EP-1831206-A2 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY OSI Pharmaceuticals, Inc. (US) 2007-09-12 EP disclosed
WO-2006060381-A2 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY OSI PHARMACEUTICALS, INC. (US) 2006-06-08 WO disclosed
US-20060116402-A1 N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library OSI PHARMACEUTICALS, INC. 2006-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060116402-A1 N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library KIT, CHUK, TNNI3K ASAH1 3555/4885APAF1 3010/4885KDM4E 1478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.